MHRA (UK)Medicines and Healthcare Products Regulatory Agency

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK competent authority for the regulation of medicines, medical devices + blood components for transfusion. It is an executive agency of the UK Department of Health and Social Care (DHSC), created in 2003 by merging the Medicines Control Agency (MCA) + the Medical Devices Agency (MDA). MHRA's remit covers human medicines (not veterinary — that's the VMD), medical devices including IVDs, blood + blood components, and (with the Health Research Authority) the regulation of clinical trials of investigational medicinal products under the UK Clinical Trials Regulations.

Post-Brexit (effective 1 Jan 2021 after the transition period), MHRA exited the EU centralised system and now operates as a sovereign regulator. Marketing authorisations granted by EMA + the European Commission ceased to be automatically valid in Great Britain (England, Scotland, Wales). Northern Ireland operates under the Windsor Framework arrangements — EU rules continue to apply for medicines + (currently) for devices with NI-specific dual-mark / single-supply arrangements.

MHRA has three main operational divisions: (1) the licensing division for medicines marketing authorisations + clinical-trial approvals, (2) the inspectorate for GMP / GDP / GCP / GLP / GPvP inspections, and (3) the devices division for medical-device regulation + market surveillance. MHRA also hosts the National Institute for Biological Standards and Control (NIBSC) — the UK reference laboratory for biological standards + reagents — and the Clinical Practice Research Datalink (CPRD).

Brexit fundamentally reshaped MHRA's relationship with EMA + the EU regulatory system. The key elements:

• Sovereign UK marketing authorisations — MHRA grants its own UK marketing authorisations (UKMAs) effective in Great Britain. Pre-Brexit centralised authorisations were converted to GB MAs through the 'grandfathering' process completed 1 Jan 2021.
• Windsor Framework (replacing the original NI Protocol, in force from 1 Jan 2025 for medicines) — for Northern Ireland, the EU rules now apply for prescription medicines through the new UK-wide MA route, with the UK fully responsible for licensing throughout the UK. Pre-Windsor, NI followed EU centralised + EU rules; the Framework now permits UK-wide single-pack supply.
• European Commission Decision Reliance Procedure (ECDRP) — operated 1 Jan 2021 to 31 Dec 2023 as a transitional bridge; MHRA could rely on positive CHMP opinions + EC decisions to grant UKMAs on a faster track.
• International Recognition Procedure (IRP) — replaced ECDRP from 1 Jan 2024; MHRA recognises decisions from seven Reference Regulators (FDA, EMA, Health Canada, TGA, Swissmedic, PMDA, Singapore HSA). Two routes: Recognition Route A (60 UK days, near-identical product to the reference decision) and Route B (110 UK days, where adaptations are needed).
• ILAP — Innovative Licensing and Access Pathway; UK equivalent of EMA's PRIME, providing enhanced engagement + accelerated review for innovative medicines targeting unmet need.
• UKCA mark for medical devices — UK conformity assessment mark; the transition timeline has been repeatedly extended (most recently for devices, with CE-marked devices continuing to be accepted in GB beyond 30 Jun 2030 for many categories pending the planned UK MDR reform).
• QP residency — qualified persons certifying batches for the UK market must be UK-based (post-Brexit grace periods have largely expired).
• Pharmacovigilance — Yellow Card Scheme; UK QPPV; UK PSMF or single PSMF covering the UK as a region.
• Clinical trials — separate UK Clinical Trials Information System + the new UK Combined Review (joint MHRA + HRA REC review) implemented progressively.

MHRA grants marketing authorisations via these routes:

The UK medical-device landscape post-Brexit is in transition. The current state:

• UK Medical Devices Regulations 2002 (as amended) — derived from the pre-MDR EU directives (MDD 93/42/EEC, AIMDD 90/385/EEC, IVDD 98/79/EC). This is the legacy regime that still governs most GB device placement.
• UKCA mark — the UK Conformity Assessed mark, intended to replace CE in GB. Transition has been repeatedly extended; CE-marked devices continue to be accepted for placement in GB beyond 30 Jun 2030 for many device categories under the latest transitional arrangements, pending the planned UK MDR reform package.
• UK Approved Bodies — the UK equivalent of EU Notified Bodies; assess UKCA conformity. Limited capacity has been a key driver of the extended CE-acceptance transition.
• Northern Ireland — under the Windsor Framework arrangements, EU MDR / IVDR apply for NI-placed devices; CE marking + EU Notified Body certificates required for NI supply.
• Post-Market Surveillance Regulations 2024 — in force 16 Jun 2025; GB-specific PMS regime aligned in substance with EU MDR Article 83-86 PMS requirements (PMS plan, PMS report, PSUR cadence by class, vigilance reporting timelines).
• Future UK MDR reform — the wider reform (intended to substantially align with EU MDR / IVDR substance while preserving UK-specific elements) is being implemented in stages; the PMS regs are the first major tranche delivered.
• Vigilance — UK manufacturer reporting to MHRA via the MORE (Manufacturer's On-Line Reporting Environment) portal; serious incident reports within 10 days (within 30 days for non-serious-but-recurrent malfunctions), corrective field-safety actions notified before customer execution.
• UDI — planned for the future UK MDR; currently mandated for NI-placed devices under the Windsor Framework via EU MDR.
• Registration — manufacturers (or UK Responsible Person for non-UK manufacturers) must register with MHRA before placing devices on the UK market.

MHRA's inspectorate enforces UK GMP (substantively aligned with EU GMP including Annexes 1-21), UK GDP (good distribution practice), UK GCP (good clinical practice for trials), UK GLP (good laboratory practice for nonclinical safety studies), UK GPvP (good pharmacovigilance practice).

• Mutual Recognition Agreement (MRA) with EU — the post-Brexit MRA recognises MHRA + EU member state inspections for GMP, avoiding duplicate inspections.
• MRA with FDA — MHRA + FDA mutually recognise GMP inspections of human medicine manufacturing sites within scope.
• PIC/S membership — MHRA is a Pharmaceutical Inspection Co-operation Scheme participating authority.
• Inspection findings categorised Critical / Major / Other; recurrent Critical findings can trigger refused certification, Statement of Non-Compliance (SoNC), or licence suspension.
• EudraGMDP — for products covered by the EU MRA, MHRA GMP certificates appear in EudraGMDP; for sovereign UK certificates, the MHRA's own register applies.
• Risk-based inspection cadence — typical 2-3 year cycle for sterile manufacturing, longer for low-risk product types.
• Annexes 1 (sterile manufacture, fully revised 2022 + in force 25 Aug 2023), 11 (computerised systems), 15 (qualification + validation), 16 (QP certification), 21 (importation) — all adopted into UK GMP.
• Data integrity — MHRA was a global leader on the 2015 'GxP Data Integrity Definitions and Guidance for Industry'; ALCOA+ principles enforced at every inspection.

• Yellow Card Scheme — the UK adverse-drug-reaction reporting system (also receives reports for medical devices, defective medicines, safety concerns in vaccines); accepts reports from healthcare professionals, patients, and MAHs.
• MAH ICSR reporting — serious + non-serious ICSRs to MHRA on the same E2B(R3) format as EU EudraVigilance; the post-Brexit submission route is MHRA's ICSR Submissions portal.
• UK QPPV — Qualified Person Responsible for Pharmacovigilance must be resident + operational in the UK (or be the UK-based representative of an EU-based QPPV under specific transitional arrangements).
• Pharmacovigilance System Master File (PSMF) — required; UK-specific PSMF or a global PSMF with UK addendum is acceptable.
• Periodic Safety Update Reports (PSURs) — UK PSUR cycle aligned with the EU EURD list where the active substance is on the list; MHRA assessment may align with the EU outcome via reliance or may diverge.
• Risk Management Plans (RMPs) — UK RMPs follow GVP Module V structure; additional risk-minimisation measures (aRMM) implemented via UK-specific educational materials, patient cards, controlled distribution.
• Signal management — MHRA Signal Management process feeds into safety reviews + variation requirements; outputs published as Drug Safety Updates.
• Black-triangle scheme — additional monitoring symbol on UK SmPC + Patient Information Leaflet for products subject to additional monitoring (typically new active substances first 5 years, conditional MAs, certain biologics).
• Pregnancy Prevention Programmes (PPP) — UK-specific implementation for teratogenic substances (e.g. isotretinoin, valproate).
• Drug Safety Update (DSU) — MHRA's monthly safety bulletin to healthcare professionals.

• Failure to convert centralised MA to a GB MA correctly during the 2021 grandfathering process — gaps discovered years later.
• IRP eligibility misjudged — sponsor submits Route A when adaptations actually required, MHRA re-routes to Route B + clock restarts.
• Reference Regulator assessment report not provided in full — MHRA cannot conduct the recognition assessment without the full Reference assessment package.
• UK Module 1 errors — UK-specific administrative content (SmPC, PIL with UK braille requirements, prescriber + dispenser categories, MHRA license-holder details) deferring validation.
• Windsor Framework misapplication — NI-supply path mistakenly used for GB-only product or vice versa; pack labelling not aligned with the supply destination.
• QP residency — non-UK QP signing UK batches without the proper UK-based representative arrangement.
• GMP Annex 1 (2022 revision) compliance gap — contamination control strategy (CCS) not in place or not signed off; CCAS audit findings at GMP inspection.
• Data integrity findings — ALCOA+ gaps; ungoverned hybrid (paper + electronic) systems; audit-trail review not performed or not evidenced.
• Yellow Card / ICSR reporting late — beyond the 15-day SUSAR or 90-day non-serious timeline.
• UK PSMF outdated or not differentiated from a global PSMF in a way MHRA accepts.
• Variation classification disputes — UK variation reclassified upward (e.g. IB to II), restarting clock + adding fees.
• UK PSUR cycle out of sync with EU EURD list cycle; double-cycle administration burden.
• GB device PMS not aligned with the 16 Jun 2025 regulations — PMS plan not in place for legacy CE-marked devices placed on the GB market.
• UKCA-mark transition — manufacturer assumed transition continued indefinitely; failed to maintain CE certificate + UK Responsible Person.
• Clinical-trial submission via the new Combined Review without UK-specific Module 1 content — UK REC + MHRA queries delaying study start.

• IRP submission count by route (A vs B) + first-time acceptance rate.
• Reference Regulator decision-to-UK-MA cycle time vs IRP target (60 / 110 UK days).
• Sovereign UK national-route application cycle time vs 150 UK-day target.
• Variation cycle time by type (IA / IB / II / Extension).
• Yellow Card ICSR on-time submission rate.
• UK QPPV continuity (no gaps) + UK PSMF freshness (last review date within policy).
• PSUR on-time submission rate; alignment-with-EU-cycle rate.
• GMP inspection outcomes (Critical / Major / Other count); Statements of Non-Compliance.
• GB device PMS plan in place per device family; vigilance reporting on-time rate to MORE portal.
• UKCA-mark transition status per device line; UK Responsible Person continuity for non-UK manufacturers.
• Windsor Framework GB / NI supply-split labelling accuracy.
• Combined Review clinical-trial application turnaround time.

V5 Ultimate runs the GMP + Quality System + pharmacovigilance evidence layer that sits beneath every MHRA-supervised activity. Specifically:

• UK GMP + Annex 11 control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls aligned with the UK equivalent of the EU + US frameworks.
• UK QP release evidence — batch certification workflow with UK QP electronic-signature + supporting evidence (batch record, deviation log, OOS / OOT review, in-process + finished-product test results) compiled per the UK adoption of Annex 16.
• IRP submission packaging — eCTD with UK Module 1, Reference Regulator assessment-report import, adaptation rationale + UK-specific content (SmPC, PIL, packaging) staged for Route A or Route B submission.
• Variation routing engine — change-control classifies proposed changes into UK Type IA / IB / II / Extension with supporting evidence package staged.
• UK PSUR + RMP coordination — cycle calendar that can align with the EU EURD list or operate UK-specific; safety + benefit-risk content prepared from the PV system + clinical-update log.
• Yellow Card / ICSR generation — E2B(R3)-format ICSRs from the complaint + adverse-event intake module submitted via the MHRA ICSR portal.
• UK PSMF — living document with UK location, version-controlled, inspection-ready; differentiation from a global PSMF where appropriate.
• GMP Annex 1 (2022) contamination-control strategy support — CCS authoring, signature workflow, inspection-readiness export.
• GB device PMS — PMS plan + PMS report + PSUR cadence aligned with the 16 Jun 2025 UK regulations; vigilance routing to the MORE portal.
• UKCA / CE dual-track — for manufacturers placing devices on GB + NI, parallel evidence tracking with UKCA + CE certificates + UK Responsible Person + Authorised Representative coordination.
• Combined Review clinical-trial application support — UK-specific Module 1 content, REC + MHRA artefact preparation, parallel-review status tracking.